Arndt Vogel: TACE combined with lenvatinib and pembrolizumab vs placebo for intermediate HCC
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a recent paper by him and colleagues on X:
“Off the press: TACE combined with lenvatinib and pembrolizumab vs placebo for intermediate HCC.
LEAP-012 phase 3.
ORR: 47 vs 33%, PFS 14.6 vs 10 months.
Proof of concept: TACE plus ICI improves outcomes.”
Authors: Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Arndt Vogel, et al.
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.
He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
More posts featuring Arndt Vogel.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023